APTO Aptose Biosciences Inc

Price (delayed)

$2.69

Market cap

$239.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$156.76M

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics ...

Highlights
The debt has contracted by 36% YoY and by 13% from the previous quarter
Aptose Biosciences's net income has decreased by 38% YoY but it has increased by 3.8% from the previous quarter
Aptose Biosciences's equity has increased by 24% YoY but it has decreased by 10% QoQ
The quick ratio has decreased by 36% from the previous quarter and by 14% YoY

Key stats

What are the main financial stats of APTO
Market
Shares outstanding
88.95M
Market cap
$239.27M
Enterprise value
$156.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$57.66M
EBITDA
-$57.05M
Free cash flow
-$37.87M
Per share
EPS
-$0.64
Free cash flow per share
-$0.43
Book value per share
$1.1
Revenue per share
$0
TBVPS
$1.19
Balance sheet
Total assets
$106.21M
Total liabilities
$8.03M
Debt
$829,000
Equity
$98.19M
Working capital
$97.6M
Liquidity
Debt to equity
0.01
Current ratio
13.67
Quick ratio
13.41
Net debt/EBITDA
1.45
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-47.8%
Return on equity
-50.6%
Return on invested capital
-311.3%
Return on capital employed
-58.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APTO stock price

How has the Aptose Biosciences stock price performed over time
Intraday
-0.37%
1 week
-6.92%
1 month
7.17%
1 year
-54.17%
YTD
-38.58%
QTD
-18.98%

Financial performance

How have Aptose Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$57.79M
Net income
-$57.66M
Gross margin
N/A
Net margin
N/A
Aptose Biosciences's net income has decreased by 38% YoY but it has increased by 3.8% from the previous quarter
The company's operating income fell by 36% YoY but it rose by 4% QoQ

Growth

What is Aptose Biosciences's growth rate over time

Valuation

What is Aptose Biosciences stock price valuation
P/E
N/A
P/B
2.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 9% since the previous quarter but it has declined by 4.9% year-on-year
The price to book (P/B) is 39% less than the 5-year quarterly average of 4.0 and 36% less than the last 4 quarters average of 3.8
Aptose Biosciences's equity has increased by 24% YoY but it has decreased by 10% QoQ

Efficiency

How efficient is Aptose Biosciences business performance
Aptose Biosciences's ROIC has plunged by 55% YoY and by 11% from the previous quarter
APTO's return on equity is up by 13% year-on-year and by 8% since the previous quarter
The return on assets rose by 11% year-on-year and by 8% since the previous quarter

Dividends

What is APTO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APTO.

Financial health

How did Aptose Biosciences financials performed over time
The company's total liabilities rose by 39% QoQ and by 32% YoY
The company's current ratio fell by 36% QoQ and by 13% YoY
The debt is 99% less than the equity
APTO's debt to equity has dropped by 50% year-on-year
The debt has contracted by 36% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.